Trial Profile
Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 16 Nov 2022 Status changed from active, no longer recruiting to completed.
- 27 Oct 2022 This trial has been completed in Netherlands (End Date: 11 Aug 2022) according to European Clinical Trials Database record.
- 23 Oct 2022 This trial has been completed in Sweden according to European Clinical Trials Database record.